Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merit Medical Systems (MMSI) Gains from Sales and Divestitures (2016 - 2024)

Historic Gains from Sales and Divestitures for Merit Medical Systems (MMSI) over the last 12 years, with Q4 2024 value amounting to $47000.0.

  • Merit Medical Systems' Gains from Sales and Divestitures fell 2295.08% to $47000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $47000.0, marking a year-over-year decrease of 2295.08%. This contributed to the annual value of $47000.0 for FY2024, which is 2295.08% down from last year.
  • As of Q4 2024, Merit Medical Systems' Gains from Sales and Divestitures stood at $47000.0, which was down 2295.08% from $61000.0 recorded in Q4 2023.
  • In the past 5 years, Merit Medical Systems' Gains from Sales and Divestitures registered a high of $61000.0 during Q4 2023, and its lowest value of $34000.0 during Q4 2021.
  • Its 4-year average for Gains from Sales and Divestitures is $46500.0, with a median of $45500.0 in 2022.
  • In the last 5 years, Merit Medical Systems' Gains from Sales and Divestitures soared by 3863.64% in 2023 and then crashed by 2295.08% in 2024.
  • Quarter analysis of 4 years shows Merit Medical Systems' Gains from Sales and Divestitures stood at $34000.0 in 2021, then grew by 29.41% to $44000.0 in 2022, then surged by 38.64% to $61000.0 in 2023, then decreased by 22.95% to $47000.0 in 2024.
  • Its Gains from Sales and Divestitures was $47000.0 in Q4 2024, compared to $61000.0 in Q4 2023 and $44000.0 in Q4 2022.